Approval · Notice of Compliance 26557 · 2021
NAT-LENALIDOMIDE: Notice of Compliance 26557
Issued September 1, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26557
- Date
- September 1, 2021
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- REVLIMID (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-LENALIDOMIDE | 02493837 | Marketed |
| NAT-LENALIDOMIDE | 02493845 | Marketed |
| NAT-LENALIDOMIDE | 02493853 | Approved |
| NAT-LENALIDOMIDE | 02493861 | Marketed |
| NAT-LENALIDOMIDE | 02493888 | Marketed |
| NAT-LENALIDOMIDE | 02493896 | Marketed |
| NAT-LENALIDOMIDE | 02493918 | Marketed |
Medicinal ingredients
- LENALIDOMIDE 2.5 MG per CAP
- LENALIDOMIDE 5 MG per CAP
- LENALIDOMIDE 7.5 MG per CAP
- LENALIDOMIDE 10 MG per CAP
- LENALIDOMIDE 15 MG per CAP
- LENALIDOMIDE 20 MG per CAP
- LENALIDOMIDE 25 MG per CAP